Managing type 2 diabetes in the primary care setting: Beyond glucocentricity

American Journal of the Medical Sciences

Volumn 340, Issue 2, 2010, Pages 133-143

  Kuritzky, Louis ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Diabetes management; Exenatide; Incretins; Individualized treatment; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; NITRILE; PEPTIDE; PIPERIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; URACIL; VENOM;

ADJUVANT THERAPY; ADULT; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REGULATORY MECHANISM; RETINOPATHY; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT GAIN; GLUCOSE BLOOD LEVEL; METABOLISM; PERSONALIZED MEDICINE; PRIMARY HEALTH CARE; RISK FACTOR;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; NITRILES; OBESITY; PATIENT COMPLIANCE; PEPTIDES; PIPERIDINES; PRIMARY HEALTH CARE; PYRAZINES; PYRROLIDINES; RISK FACTORS; TRIAZOLES; URACIL; VENOMS;

EID: 77956052311     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181d64344     Document Type: Review

References (71)

1. Suadicani P, Hein HO, Eyben FE, et al. Metabolic and lifestyle predictors of ischemic heart disease and all-cause mortality among normal weight, overweight, and obese men: a 16-year follow-up in the Copenhagen Male Study. Metab Syndr Relat Disord 2009;7:97-104.
2. National Diabetes Information Clearinghouse. National diabetes statistics, 2007. Available at: http://diabetes.niddk.nih.gov/dm/pubs/ statistics/. Last update: June 2008. Accessed July 24, 2009.
3. American Diabetes Association. Standards of medical care in diabetes- 2009. Diabetes Care 2009;32(suppl 1):S1- 61.
4. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
5. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-453
6. Stonehouse AH, Holcombe JH, Kendall DM. Management of type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother 2006;7:2095-2105
7. Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(suppl 1):1-68.
8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-549
9. Monnier L, Collette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008;31(suppl 2):S150-4.
10. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
11. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(suppl 2):B21-9.
12. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
13. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
14. Duckworth WC, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
15. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192
16. Reaven PD, Moritz TE, Schwenke DC, et al; Veterans Affairs Diabetes Trial. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009;58:2642-2648
17. Ménard J, Payette H, Dubuc N, et al. Quality of life in type 2 diabetes patients under intensive multitherapy. Diabetes Metab 2007;33:54-60.
18. Daly JM, Hartz AJ, Xu Y, et al. An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes. J Am Board Fam Med 2009;22:280-290
19. Delamater AM. Improving patient adherence. Clin Diabetes 2006;24: 71-77
20. Edelman S, Dailey G, Flood T, et al. A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care 2007;1:9.
21. Garfield S, Smith F, Francis SA, et al. Can patients' preferences for involvement in decision-making regarding the use of medicines be predicted? Patient Educ Couns 2007;66:361-367
22. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31:213-224
23. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med 2008;120:172-179
24. Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008;120:5-17.
25. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
26. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
27. Nicolucci A, Rossi MC. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008;79:184-191
28. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30: 1487-1493
29. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009;8:369-385
30. Nauck MA, Ratner RE, Kapitza C, et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with MET alone: a double-blind placebo-controlled study. Diabetes Care 2009;32: 1237-1243
31. Matthews JE, Stewart MW, De Boever EH, et al; Albiglutide Study Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-4817
32. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386
33. Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009;37:1164-1171
34. DeFronzo RA, Fleck PR, Wilson CA, et al; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-2317
35. Byetta exenatide BID [package insert]. San Diego (CA): Amylin Pharmaceuticals, Inc.; 2009.
36. Buse JB, Henry RR, Han J, et al; Exenatide-113 Clinical Study Group. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635
37. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin- 4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100
38. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091
39. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
40. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348
41. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267
42. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther 2008;30:1448-1460
43. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286
44. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-2952
45. Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, open-label trial (LEAD-6). Lancet 2009;374:39-47.
46. Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372:1240-1250
47. Marre M, Shaw J, Brändle M, et al; LEAD-1 SU Study Group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
48. Nauck MA, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
49. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
50. Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
51. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055
52. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-180
53. Charbonnel B, Karasik A, Liu J, et al; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643
54. Rosenstock J, Brazg R, Andryuk PJ, et al; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther 2006;28:1556-1568
55. Rosenstock J, Aguilar-Salinas C, Klein E, et al; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naíve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411
56. DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655
57. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622
58. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194-206.
59. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-786
60. Idris I. FDA reviews incidences of acute pancreatitis in patients taking Byetta. Diabetes Obes Metab 2008;10:96-98
61. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-1027
62. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-838
63. Kim T, Taylor K, Wilhelm K, et al. Exenatide once weekly treatment elicits sustained glycemic control and weight loss over 2 years. Program and abstracts of the American Diabetes Association (ADA) 69th Scientific Sessions, New Orleans, LA, June 5-9, 2009; Abstract 159-OR.
64. Madsbad S. Liraglutide effect and action in diabetes (LEAD) trial. Expert Rev Endocrinol Metab 2009;4:119-129
65. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619
66. Januvia (sitagliptin) Tablets [package insert]. Whitehouse Station, (NJ): Merck & Co., Inc.; 2009.
67. U.S. Food and Drug Administration. Information for healthcare professionals- acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). September 25, 2009. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandP roviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed December 3, 2009.
68. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes. Drugs 2008;68:2387-2409
69. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008; 5:73-94.
70. Nauck MA, Ellis GC, Fleck PR, et al; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomized, doubleblind, placebo-controlled study. Int J Clin Pract 2009;63:46-55.
71. Pratley RE, Kipnes MS, Fleck PR, et al; Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-176